Plex Pharmaceuticals remains driven to improve the lives of patients with complex diseases and disorders.
Plex discovered multiple lead series of small molecule activators of alpha-crystallin that show promising efficacy in dissolving aggregates in cell model for the treatment of cataracts. Target molecule(s) realign and/or prevent the formation of protein clusters as a result of cataracts, to a normal configuration which eliminates the potential need for current invasive surgical procedures. Plex is preparing a regulatory information package for an IND.
Plex's drug candidate has the potential to disrupt the $4 Billion dollar-plus, global surgical cataract device market.
Plex continues to advance its other drug programs including but not limited to glioblastoma, Parkinson’s disease and conjunctivitis programs into the next stage of development.